Hypertension impairs postnatal vasculogenesis -: Role of antihypertensive agents

被引:44
|
作者
You, Dong [1 ]
Cochain, Clement [1 ]
Loinard, Celine [1 ]
Vilar, Jose [1 ]
Mees, Barend [2 ]
Duriez, Micheline [1 ]
Levy, Bernard I. [1 ]
Silvestre, Jean-Sebastien [1 ]
机构
[1] Univ Paris 07, INSERM, U Lariboisiere 689, Hop Lariboisiere,Cardiovasc Res Ctr, F-75475 Paris 10, France
[2] Erasmus Univ, Med Ctr, Dept Cell Biol & Genet Vasc Surg, Rotterdam, Netherlands
关键词
hypertension; angiogenesis; progenitor cells; angiotensin converting enzyme; angiotensin type I receptor;
D O I
10.1161/HYPERTENSIONAHA.107.109066
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We analyzed the effect of hypertension on postischemic vasculogenesis. Ischemia was induced by right femoral artery ligature in Wistar Kyoto rats (WKY) or spontaneously hypertensive rats (SHR) treated with or without angiotensin-converting enzyme inhibitor (Perindopril, 0.76 mg/kg/d) and angiotensin type 1 receptor blocker (losartan, 30 mg/kg/d). Basal postischemic neovascularization was reduced in SHR compared to WKY (P<0.05, n=8). Treatment with ACE inhibitor or angiotensin type 1 receptor blocker decreased blood pressure levels by 1.4- and 1.3-fold (P<0.001), respectively and restored vessel growth in SHR to WKY levels. Interestingly, 14 days after bone-marrow mononuclear cell (BM-MNC) transfusion, angiographic scores, capillary density, and foot perfusion were decreased by 1.4-, 1.5-, and 1.2-fold, respectively in SHR transfused with BM-MNCs isolated from SHR compared to those receiving BM-MNCs of WKY (P<0.05, n = 6). Alteration in BM-MNCs proangiogenic potential was likely related to the reduction in their ability to mobilize into peripheral circulation, as revealed by the 2.9-fold decrease in number of circulating CD34+/CD117+ cells (P < 0.001) and to differentiate into cells with endothelial phenotype, as revealed by the 2.1-fold reduction in percentages of DilLDL/BS-1 lectin positive cells (P < 0.001). In addition, reactive oxygen species (ROS) levels were increased by 2.2-fold in SHR BM-MNCs compared to WKY BM-MNCs (P < 0.01), as assessed by L-012 luminescence. Cotreatment with ACE inhibitor, angiotensin type 1 receptor blocker, or antioxidants (NAC 3 mmol/L, Apocynin 200 mu mol/L) reduced ROS levels, improved the number of DilLDL/BS-1 lectin-positive cells by around 1.5- fold, and restored BM-MNCs proangiogenic effects in ischemic hindlimb. In conclusion, alteration in progenitor cell proangiogenic function may participate to the hypertension-induced impairment in postischemic revascularization.
引用
收藏
页码:1537 / 1544
页数:8
相关论文
共 50 条
  • [1] HYPERTENSION AND ANTIHYPERTENSIVE AGENTS
    DELFOSSE, M
    JOURNAL DE PHARMACIE DE BELGIQUE, 1986, 41 (06) : 418 - 439
  • [2] Postnatal vasculogenesis
    Ribatti, D
    Vacca, A
    Nico, B
    Roncali, L
    Dammacco, F
    MECHANISMS OF DEVELOPMENT, 2001, 100 (02) : 157 - 163
  • [3] Systemic hypertension and antihypertensive agents
    Maschio, G
    Marcantoni, C
    Bernich, P
    JOURNAL OF NEPHROLOGY, 1999, 12 : S100 - S104
  • [4] ROLE OF ISRADIPINE AND OTHER ANTIHYPERTENSIVE AGENTS IN THE TREATMENT OF PERIOPERATIVE AND POSTOPERATIVE HYPERTENSION
    MARTY, J
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1993, 37 : 53 - 55
  • [5] HYPERTENSION AND ANTIHYPERTENSIVE AGENTS .2.
    GIROUIN, JY
    LYON PHARMACEUTIQUE, 1979, 30 (01): : 19 - 31
  • [6] The changing face of hypertension and antihypertensive agents
    Kitler, ME
    DRUGS & AGING, 1996, 8 (01) : 5 - 11
  • [7] Statins in Hypertension: Are They a New Class of Antihypertensive Agents?
    Feldstein, Carlos A.
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (03) : 255 - 262
  • [8] AN IN VIVO EXPERIMENTAL MODEL FOR POSTNATAL VASCULOGENESIS
    Melero-Martin, Juan M.
    Bischoff, Joyce
    ANGIOGENESIS: IN VIVO SYSTEMS, PT B, 2008, 445 : 303 - 329
  • [9] Endothelial progenitor cells for postnatal vasculogenesis
    Eguchi M.
    Masuda H.
    Asahara T.
    Clinical and Experimental Nephrology, 2007, 11 (1) : 18 - 25
  • [10] Hypertension, antihypertensive agents and outcomes following renal transplantation
    Tutone, VK
    Mark, PB
    Stewart, GA
    Tan, CC
    Rodger, RSC
    Geddes, CC
    Jardine, AG
    CLINICAL TRANSPLANTATION, 2005, 19 (02) : 181 - 192